---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000178"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:17:36.995018+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024

## Summary
- Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.
- Also expects $200M transaction-related compensation expense for acceleration of unvested Alpine equity awards in Q2 2024.
- Charges will impact GAAP and non-GAAP operating expenses and net income for Q2 and full year 2024, and related guidance.
- Vertex completed Alpine acquisition for $5.0B cash on May 20, 2024; expects to absorb Alpine's non-GAAP R&D/SG&A within existing guidance.

## SEC filing metadata
- accession: 0000875320-24-000178
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000178/0000875320-24-000178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000178/vrtx-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000178
- JSON: https://secwatch.observer/filing/0000875320-24-000178.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.